AstraZeneca enters license agreement with Daiichi Sankyo for development and commercialisation of FluMist in Japan
AstraZeneca today announced that its global biologics research and development arm, MedImmune, has entered an agreement granting Daiichi Sankyo Company, Ltd. (Daiichi Sankyo) an...
Immuno-oncology: an update on progress at the European Cancer Congress
Within the rapidly evolving world of cancer treatment and the excitement surrounding immuno-oncology, it is more important than ever to have a strategic approach...
AstraZeneca presents advances in oncology research at ECC 2015 with data on AZD9291, durvalumab and LYNPARZA™ (olaparib)
AstraZeneca, along with MedImmune, the company’s global biologics research and development arm, will illustrate the strength and depth of research underpinning its scientific leadership...
New England Journal of Medicine publishes results of head-to-head studies of brodalumab versus ustekinumab in psoriasis
The New England Journal of Medicine (NEJM) has published positive results from two pivotal, multi-centre, Phase III studies –AMAGINE-2 and AMAGINE-3 – demonstrating that...
AstraZeneca and Lilly expand immuno-oncology research collaboration with new combinations
AstraZeneca and Eli Lilly and Company (Lilly) today announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of...
Lilly To Discontinue Development Of Evacetrapib For High-Risk Atherosclerotic Cardiovascular Disease
Eli Lilly and Company (NYSE: LLY) and the ACCELERATE study's academic leadership have accepted the recommendation of the independent data monitoring committee to terminate...
Allergan and Humana Announce Research Partnership to Improve Health Outcomes
Allergan plc (NYSE: AGN), a leading global specialty pharmaceutical company, today announced a multi-year research collaboration with Humana Inc. (NYSE: HUM), one of the...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...